Roche is looking to use Dyno’s technologies to target neurological diseases, a big focus at the Swiss pharma, with multiple sclerosis blockbuster Ocrevus serving as its best-selling asset.
In September, the Swiss pharma won back-to-back FDA approvals for subcutaneous versions of its multiple sclerosis drug Ocrevus and cancer immunotherapy Tecentriq. Dubbed Ocrevus Zunovo ...
Roche’s top-performing asset was the multiple sclerosis drug Ocrevus; sales increased 11% to 1.69 billion Swiss francs. Sales of Vabysmo, an age-related macular degeneration (AMD) treatment ...
While pricing power and demand for Biogen's injectable MS portfolio are eroding in the face of new competition, Biogen receives substantial royalties on Roche's popular drug Ocrevus, which helps ...
Today, a brief rundown of news from Merck & Co. and Roche, as well as updates from Sangamo Therapeutics, UCB and Catalent that you may have missed. MacroGenics, a developer of antibody medicines for ...
Denn das sei schon aufgrund der Wirkweise der Pille sehr unwahrscheinlich. Durch die Hormone in der Pille wird dem Körper vorgegaukelt, dass sich der Körper in der sogenannten Lutealphase ...
Gilenya® darf weder bei Patienten angewendet werden, bei denen aufgrund eines geschwächten Immunsystems ein Infektionsrisiko besteht, noch bei Patienten mit einer schweren Infektion oder einer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback